Biotechnology company, Biogen has announced the identification of a
molecule that may play a key role in the repair and regeneration of
the central nervous system (CNS). The finding could lead to
potential pathways for treating multiple...
Switzerland's Siegfried Group, a specialist in active
pharmaceutical ingredients (APIs), dosage forms and
biopharmaceuticals, has boosted its position in the production of
controlled substances with the acquisition of US-based...
The first genetic disease that affects the central nervous system
has been successfully treated in an animal model, which if
successfully applied to humans, could treat an entire class of
diseases called lysosomal storage disorders....
The first study to confirm the potential of a new class of drug for
neurodegenerative disorders such as Alzheimer's could herald a
breakthrough in drug treatment for a disease that affects up to 4
million adults in the United...
US target discovery company Psychiatric Genomics has shed new light
on the mechanisms behind schizophrenia, pointing to a possible new
cellular target that does not rely on modulating the levels of
neurotransmitters in the brain.
Efforts to improve the efficacy of cancer therapy by blocking
cellular mechanisms that underlie resistance to cytotoxic drugs
have promised much but delivered little to date. Now, a team of
researchers in the US believe they have...
Scientists who have discovered the binding site for the
anti-epilepsy drug Keppra have confirmed that the drugs mechanism
of action places it in a new class of central nervous system (CNS)
drugs.
Researchers have developed the first tool to identify and study
individual neurons activated in a living animal, ultimately leading
to the development of targeted drugs that directly affect neurons
involved in neurological diseases...
Belgian chemicals and pharmaceuticals company UCB has made an offer
to buy UK biotechnology firm Celltech for £1.53 billion (€2.25bn)
in a move seen as a way of getting hold of the latter's much-touted
arthritis drug.
A scientist has claimed that nanotechnology - devoted to
engineering tiny machines with applications as diverse as drug
delivery, electronics and materials science - could pose a health
hazard and should be investigated further before...
Germany's Evotec Neurosciences, a subsidiary of Evotec OAI, has
licensed rights to a patent portfolio developed by Roche that
covers a promising - but elusive - drug target for central nervous
system (CNS) disorders, reports...
Dutch formulation specialist ForTe has developed a new taste-masked
formulation of sodium phenylbutyrate, used in the treatment of a
group of rare metabolic disorders characterised by an inability to
eliminate waste nitrogen, that...
The days when cigarettes were held up in advertising as healthy
products are long gone, but new research suggests there may be some
substance to this - at least for some disorders affecting the
brain.
